Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Retained Earnings for 6 consecutive years, with -$110.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 10.69% year-over-year to -$110.9 million, compared with a TTM value of -$110.9 million through Dec 2025, up 10.69%, and an annual FY2025 reading of -$110.9 million, up 10.69% over the prior year.
  • Retained Earnings was -$110.9 million for Q4 2025 at SAB Biotherapeutics, down from -$94.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $26420.0 in Q4 2023 and bottomed at -$129.4 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$57.8 million, with a median of -$51.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings soared 100.06% in 2023, then tumbled 470080.51% in 2024.
  • Year by year, Retained Earnings stood at -$29.1 million in 2021, then tumbled by 64.34% to -$47.9 million in 2022, then skyrocketed by 100.06% to $26420.0 in 2023, then crashed by 470080.51% to -$124.2 million in 2024, then increased by 10.69% to -$110.9 million in 2025.
  • Business Quant data shows Retained Earnings for SABS at -$110.9 million in Q4 2025, -$94.0 million in Q3 2025, and -$15805.0 in Q2 2025.